|
1
|
Tsai MJ and O'Malley BW: Molecular
mechanisms of action of steroid/thyroid receptor superfamily
members. Ann Rev Biochem. 63:451–486. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mangelsdorf DJ and Evans RM: The RXR
heterodimers and orphan receptors. Cell. 83:841–850. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Biron E and Bedard F: Recent progress in
the development of protein-protein interaction inhibitors targeting
androgen receptor-coactivator binding in prostate cancer. J Steroid
Biochem Mol Biol. 161:36–44. 2016. View Article : Google Scholar
|
|
4
|
Dehm SM and Tindall DJ: Alternatively
spliced androgen receptor variants. Endocr Relat Cancer.
18:R183–R196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu J, Van der Steen T and Tindall DJ: Are
androgen receptor variants a substitute for the full-length
receptor? Nat Rev Urol. 12:137–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu Z, Chen S, Sowalsky AG, Voznesensky OS,
Mostaghel EA, Nelson PS, Cai C and Balk SP: Rapid induction of
androgen receptor splice variants by androgen deprivation in
prostate cancer. Clin Cancer Res. 20:1590–1600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yin Y, Li R, Xu K, Ding S, Li J, Baek G,
Ramanand SG, Ding S, Liu Z, Gao Y, et al: Androgen receptor
variants mediate DNA repair after prostate cancer irradiation.
Cancer Res. 77:4745–4754. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W,
Gambhir SS, Lee P, Sartor O, Flemington EK, et al: Androgen
receptor splice variants dimerize to transactivate target genes.
Cancer Res. 75:3663–3671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu R, Lu C, Mostaghel EA, Yegnasubramanian
S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E,
et al: Distinct transcriptional programs mediated by the
ligand-dependent full-length androgen receptor and its splice
variants in castration-resistant prostate cancer. Cancer Res.
72:3457–3462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wach S, Taubert H and Cronauer M: Role of
androgen receptor splice variants, their clinical relevance and
treatment options. World J Urol. 38:647–656. 2020. View Article : Google Scholar
|
|
12
|
Guo Z, Yang X, Sun F, Jiang R, Linn DE,
Chen H, Chen H, Kong X, Melamed J, Tepper CG, et al: A novel
androgen receptor splice variant is up-regulated during prostate
cancer progression and promotes androgen depletion-resistant
growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharp A, Coleman I, Yuan W, Sprenger C,
Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G,
et al: Androgen receptor splice variant-7 expression emerges with
castration resistance in prostate cancer. J Clin Invest.
129:192–208. 2019. View Article : Google Scholar :
|
|
14
|
Honda M, Kimura T, Kamata Y, Tashiro K,
Kimura S, Koike Y, Sato S, Yorozu T, Furusato B, Takahashi H, et
al: Differential expression of androgen receptor variants in
hormone-sensitive prostate cancer xenografts, castration-resistant
sublines, and patient specimens according to the treatment
sequence. Prostate. 79:1043–1052. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paschalis A, Sharp A, Welti JC, Neeb A,
Raj GV, Luo J, Plymate SR and de Bono JS: Alternative splicing in
prostate cancer. Nature Rev Clin Oncol. 15:663–675. 2018.
View Article : Google Scholar
|
|
16
|
Scher HI, Graf RP, Schreiber NA, Jayaram
A, Winquist E, McLaughlin B, Lu D, Fleisher M, Orr S, Lowes L, et
al: Assessment of the validity of nuclear-localized androgen
receptor splice variant 7 in circulating tumor cells as a
predictive biomarker for castration-resistant prostate cancer. JAMA
Oncol. 4:1179–1186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun S, Sprenger CC, Vessella RL, Haugk K,
Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et
al: Castration resistance in human prostate cancer is conferred by
a frequently occurring androgen receptor splice variant. J Clin
Invest. 120:2715–2730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van Etten JL, Nyquist M, Li Y, Yang R, Ho
Y, Johnson R, Ondigi O, Voytas DF, Henzler C and Dehm SM: Targeting
a single alternative polyadenylation site coordinately blocks
expression of androgen receptor mRNA splice variants in prostate
cancer. Cancer Res. 77:5228–5235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YC, Banuelos CA, Mawji NR, Wang J,
Kato M, Haile S, McEwan IJ, Plymate S and Sadar MD: Targeting
androgen receptor activation Function-1 with EPI to overcome
resistance mechanisms in castration-resistant prostate cancer. Clin
Cancer Res. 22:4466–4477. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz
CT, Evans CP and Gao AC: Niclosamide inhibits androgen receptor
variants expression and overcomes enzalutamide resistance in
castration-resistant prostate cancer. Clin Cancer Res.
20:3198–3210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moldovan GL, Pfander B and Jentsch S:
PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stoimenov I and Helleday T: PCNA on the
crossroad of cancer. Biochem Soc Transact. 37:605–613. 2009.
View Article : Google Scholar
|
|
23
|
Maga G and Hubscher U: Proliferating cell
nuclear antigen (PCNA): A dancer with many partners. J Cell Sci.
116:3051–3060. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gilljam KM, Feyzi E, Aas PA, Sousa MM,
Muller R, Vagbo CB, Catterall TC, Liabakk NB, Slupphaug G, Drabløs
F, et al: Identification of a novel, widespread, and functionally
important PCNA-binding motif. J Cell Biol. 186:645–654. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gulbis JM, Kelman Z, Hurwitz J, O'Donnell
M and Kuriyan J: Structure of the C-terminal region of
p21(WAF1/CIP1) complexed with human PCNA. Cell. 87:297–306. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu S, Lee J, Revelo M, Wang X and Dong Z:
Smad3 is overexpressed in advanced human prostate cancer and
necessary for progressive growth of prostate cancer cells in nude
mice. Clin Cancer Res. 13:5692–5702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Spires SE, Banks ER, Davey DD, Jennings
CD, Wood DP Jr and Cibull ML: Proliferating cell nuclear antigen in
prostatic adenocarcinoma: Correlation with established prognostic
indicators. Urology. 43:660–666. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kallakury BV, Sheehan CE, Rhee SJ, Fisher
HA, Kaufman RP Jr, Rifkin MD and Ross JS: The prognostic
significance of proliferation-associated nucleolar protein p120
expression in prostate adenocarcinoma: A comparison with cyclins A
and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Cancer. 85:1569–1576. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muller R, Misund K, Holien T, Bachke S,
Gilljam KM, Vatsveen TK, Ro TB, Bellacchio E, Sundan A and Otterlei
M: Targeting proliferating cell nuclear antigen and its protein
interactions induces apoptosis in multiple myeloma cells. PLoS One.
8:e704302013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smith SJ, Gu L, Phipps EA, Dobrolecki L,
Mabrey KS, Gulley P, Dillehay KL, Dong Z, Fields GB, Chen Y, et al:
A peptide mimicking a region in proliferating cell nuclear antigen
specific to key protein interactions is cytotoxic to breast cancer.
Mol Pharmacol. 87:263–276. 2015. View Article : Google Scholar :
|
|
31
|
Punchihewa C, Inoue A, Hishiki A, Fujikawa
Y, Connelly M, Evison B, Shao Y, Heath R, Kuraoka I, Rodrigues P,
et al: Identification of a small molecule PCNA inhibitor that
disrupts interactions with PIP-Box proteins and inhibits DNA
replication. J Biol Chem. 287:14289–14300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gu L, Lingeman R, Yakushijin F, Sun E, Cui
Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, et al: The anticancer
activity of a First-in-class Small-molecule targeting PCNA. Clin
Cancer Res. 24:6053–6065. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu S and Dong Z: Additive effects of a
small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on
growth inhibition and DNA damage in prostate and lung cancer cells.
PLoS One. 14:e02238942019. View Article : Google Scholar
|
|
34
|
Dillehay KL, Seibel WL, Zhao D, Lu S and
Dong Z: Target validation and structure-activity analysis of a
series of novel PCNA inhibitors. Pharmacol Res Perspect.
3:e001152015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dillehay KL, Lu S and Dong Z: Antitumor
effects of a novel small molecule targeting PCNA chromatin
association in prostate cancer. Mol Cancer Ther. 13:2817–2826.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tan Z, Wortman M, Dillehay KL, Seibel WL,
Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S and Dong Z:
Small-molecule targeting of proliferating cell nuclear antigen
chromatin association inhibits tumor cell growth. Mol Pharmacol.
81:811–819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Murthy S, Wu M, Bai VU, Hou Z, Menon M,
Barrack ER, Kim SH and Reddy GP: Role of androgen receptor in
progression of LNCaP prostate cancer cells from G1 to S phase. PLoS
One. 8:e566922013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu S, Tsai SY and Tsai MJ: Melecular
mechanisms of androgen-independent growth of human prostate cancer
LNCaP-AI cells. Endocrinology. 140:5054–5059. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nyquist MD, Li Y, Hwang TH, Manlove LS,
Vessella RL, Silverstein KA, Voytas DF and Dehm SM:
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling
of androgen receptor in prostate cancer. Proc Natl Acad Sci USA.
110:17492–17497. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dong Z, Liu Y, Scott KF, Levin L, Gaitonde
K, Bracken RB, Burk B, Zhai Q, Wang J, Oleksowicz L and Lu S:
Secretory phospholipase A2-IIa is involved in prostate cancer
progression and may potentially serve as a biomarker for Prostate
Cancer. Carcinogenesis. 31:1948–1955. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu S and Dong Z: Overexpression of
secretory phospholipase A2-IIa supports cancer stem cell phenotype
via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Int J Oncol. 50:2113–2122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu S, Tan Z, Wortman M, Lu S and Dong Z:
Regulation of heat shock protein 70-1 expression by androgen
receptor and its signaling in human prostate cancer cells. Int J
Oncol. 36:459–467. 2010.PubMed/NCBI
|
|
43
|
Simon P: Q-Gene: Processing quantitative
real-time RT-PCR data. Bioinformatics. 19:1439–1440. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dong ZY, Ward NE, Fan D, Gupta KP and
O'Brian CA: In vitro model for intrinsic drug resistance: Effects
of protein kinase C activators on the chemosensitivity of cultured
human colon cancer cells. Mol Pharmacol. 39:563–569.
1991.PubMed/NCBI
|
|
45
|
Khavrutskii L, Yeh J, Timofeeva O, Tarasov
SG, Pritt S, Stefanisko K and Tarasova N: Protein purification-free
method of binding affinity determination by microscale
thermophoresis. J Vis Exp. 50541:2013.
|
|
46
|
Leonhardt H, Rahn HP, Weinzierl P,
Sporbert A, Cremer T, Zink D and Cardoso MC: Dynamics of DNA
replication factories in living cells. J Cell Biol. 149:271–280.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Slade D: Maneuvers on PCNA Rings during
DNA replication and repair. Genes (Basel). 9:4162018. View Article : Google Scholar
|
|
48
|
Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao
P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, et al: Diverse
AR-V7 cistromes in castration-resistant prostate cancer are
governed by HoxB13. Proc Natl Acad Sci USA. 115:6810–6815. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lu S, Liu M, Epner DE, Tsai SY and Tsai
MJ: Androgen regulation of the cyclin-dependent kinase inhibitor
p21 gene through an androgen response element in the proximal
promoter. Mol Endocrinol. 13:376–384. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dai JL, Maiorino CA, Gkonos PJ and
Burnstein KL: Androgenic up-regulation of androgen receptor cDNA
expression in androgen-independent prostate cancer cells. Steroids.
61:531–539. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Manin M, Baron S, Goossens K, Beaudoin C,
Jean C, Veyssiere G, Verhoeven G and Morel L: Androgen receptor
expression is regulated by the phosphoinositide 3-kinase/Akt
pathway in normal and tumoral epithelial cells. Biochem J.
366:729–736. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jia L and Coetzee GA: Androgen
receptor-dependent PSA expression in androgen-independent prostate
cancer cells does not involve androgen receptor occupancy of the
PSA locus. Cancer Res. 65:8003–8008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Krishna TS, Kong XP, Gary S, Burgers PM
and Kuriyan J: Crystal structure of the eukaryotic DNA polymerase
processivity factor PCNA. Cell. 79:1233–1243. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kelman Z and O'Donnell M: Structural and
functional similarities of prokaryotic and eukaryotic DNA
polymerase sliding clamps. Nucleic Acids Res. 23:3613–3620. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Koryakina Y, Ta HQ and Gioeli D: Androgen
receptor phosphorylation: Biological context and functional
consequences. Endocr Relat Cancer. 21:T131–T145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dong Z, Liu Y and Lu S, Wang A, Lee K,
Wang LH, Revelo M and Lu S: Vav3 oncogene is overexpressed and
regulates cell growth and androgen receptor activity in human
prostate cancer. Mol Endocrinol. 20:2315–2325. 2006. View Article : Google Scholar : PubMed/NCBI
|
